Using a GLP-1 for weight loss

Key takeaways:

• Most adults qualify for an FDA-approved GLP-1 weight-loss medication with a BMI of 30 or higher, or a BMI of 27 or higher plus a weight-related condition such as high blood pressure or type 2 diabetes.
• Visits typically start monthly while your dose is being adjusted (titrated), then space out to roughly every three months once you're on a stable dose.
• Weight loss is usually fastest in the first several months, then slows — many people land around 15–20% of their starting weight, and that slowdown is expected, not a sign the medication has stopped working.
• These medications are built for long-term use: stopping without lasting habit changes in place typically brings back much of the weight within a year.

If you're starting a GLP-1 medication like semaglutide or tirzepatide for weight loss, the biggest surprises usually aren't about the medication itself — they're about the shape of the process: how visits are spaced, what "maintenance dose" actually means, and why the scale eventually stops moving even though the medication is still working.

Is a GLP-1 right for you?

You likely qualify if your BMI is 30 or higher, or 27 or higher with a weight-related health condition — this is the FDA-approved criteria for medications like semaglutide (Wegovy) and tirzepatide (Zepbound).

A BMI under 27 doesn't automatically rule you out, but treatment at that range is off-label and won't be covered by insurance — your clinician will walk through whether it's a fit for your specific history and goals.

Who shouldn't take a GLP-1

These medications aren't right for everyone, and FDA prescribing information lists specific situations where they're contraindicated or not recommended. Your clinician will screen for:

• A personal or family history of certain thyroid cancers (medullary thyroid carcinoma), or a rare inherited condition called Multiple Endocrine Neoplasia syndrome type 2
• Active or recent pancreatitis (inflammation of the pancreas)
• Severe gastroparesis (a stomach-emptying disorder)
• An active eating disorder or significant body image concerns
• Pregnancy, breastfeeding, or a plan to become pregnant in the next few months

This isn't a full list, and it isn't a substitute for your own intake — it's why the candidacy conversation with your clinician matters more than the BMI number alone.

Meeting with a clinician

Expect monthly check-ins at first while your dose is being adjusted, then a shift to roughly every three months once you're on a stable dose. That's the general shape most patients follow so your clinician can confirm you're tolerating the medication and not experiencing side effects — the exact cadence for your plan is something your care team will confirm directly. Between scheduled visits, you can message your care team with questions or side effects, with same-day support available during business hours.

Monitoring and testing

Some monitoring is required for safety, while other testing is tailored to your history. A typical pattern looks like this:

Finding the right dose

Your dose goes up gradually — a process called titration — until you and your clinician find the amount that works for you. That's called your maintenance dose. Reaching it isn't the finish line. It's the start of the long-term phase, and visits roughly every three months continue so your care team can track progress and adjust as needed. Some people eventually move to a lower dose, or a different form of the medication, once they've reached their goals. That's a conversation for you and your clinician, not something to decide on your own.

Taking a holistic approach

A GLP-1 medication isn't meant to work alone — in the actual studies behind it, the drug was tested on top of a reduced-calorie diet and more physical activity, not against doing nothing else. That combination is also where the numbers come from: the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reports that, on average, adults who combine a weight-management medication with healthier eating and activity lose 3 to 12 percentage points more of their starting weight after a year than healthy habits alone produce. Medications don't replace healthy eating or physical activity. They work best together.

A few pieces worth building in from the start:

• Protein and resistance training. Some of what you lose on a GLP-1 medication can be muscle, not just fat. Eating enough protein and doing strength exercise a few times a week are the main tools for protecting muscle while you lose fat. Your care team can help with guidance specific to you.
• A sustainable eating pattern, not a crash diet. The goal is a reduced-calorie plan you can actually keep up for months or years, not a short-term restriction. Your clinician or a referred dietitian can help shape one around your preferences and health history.
• Regular physical activity. General physical activity guidelines point to about 150 minutes a week of moderate-intensity movement as a starting target — walking counts. Build up gradually rather than starting at that number on week one.
• Sleep, stress, and food triggers. Lifestyle and health routines can influence weight independent of the medication. If any of these feel like the bigger obstacle, say so at a visit — it's a legitimate part of the plan, not a side conversation.

None of this is about earning the medication or proving effort — it's about what the evidence says actually drives durable results, and it's exactly the kind of thing to build into your visits with your care team rather than figure out alone.

The weight loss plateau

Weight loss on these medications tends to follow a curve, not a straight line — fast at first, then gradually leveling off. The most current, largest long-term look at this comes from SURMOUNT-1, the big clinical trial behind tirzepatide: over the first 72 weeks, participants on the highest studied dose lost an average of 20.9% of their body weight, against 3.1% on placebo. A later analysis followed participants with prediabetes out to three years (176 weeks) and found the loss held up: 19.7% at the highest dose, against 1.3% on placebo. A plateau, often somewhere in that same range, is a normal, expected part of treatment. It doesn't mean the medication has stopped working. It's usually a good moment to talk with your care team about next steps, whether that's adjusting your plan or confirming your current weight is the right target.

A few things worth knowing going in:

• This is a long-term treatment for a chronic condition — think months and years, not weeks.
• The prior authorization process for insurance coverage generally takes several business days — your care team will follow up with updates.
• That same long-term study also tracked what happens after stopping: once participants went off the medication for a stretch at the end of the trial, their weight drifted back toward where the placebo group had ended up. It's the clearest evidence behind this article's opening point — staying on track long-term matters as much as the starting dose.

More than a weight-loss drug

The same long-term study that shows the plateau also points to something bigger than the scale. Among trial participants who had prediabetes, only 1.3% who took the highest studied dose went on to develop type 2 diabetes over three years, compared with 13.3% on placebo — roughly one-tenth as many. The original trial also found improvements in blood pressure, cholesterol, and waist size, not just body weight.

It's a big enough effect that researchers increasingly talk about these medications as changing the course of the disease itself, not just helping people lose weight — the diabetes-prevention benefit stands on its own, separate from how much weight someone loses. Research is still going, including dedicated trials now looking at heart-health outcomes specifically, so what's confirmed today may well expand as more results come in. Your clinician can talk through what's established versus what's still being studied for your specific situation.

Creating a long-term plan

If you're thinking about your dose, a plateau, or what happens if you eventually stop, that's a conversation for your clinician — not a decision to make solo. Stopping a GLP-1 medication without lasting lifestyle changes in place commonly brings back much of the lost weight, which is exactly why the ongoing visits matter as much as the starting dose.

A General Medicine clinician won't be starting from zero. The history and context from your earlier visits carries forward, and your care team stays involved between check-ins so your plan doesn't reset every time you log in.

Frequently asked questions

Will I lose muscle, not just fat, on a GLP-1 medication?

It's possible — weight loss on any medication or diet can include some lean muscle along with fat. Eating enough protein and doing resistance exercise a few times a week are the main tools for protecting muscle while you lose weight; ask your care team for guidance specific to you.

Is it a problem if my weight loss is slower than someone else's?

Not on its own. Individual response varies, and your care team looks at your dose, your timeline, and your overall trend rather than comparing you to anyone else's results.

Can I switch from an injection to a pill form of the medication?

Some GLP-1 medications are now available in oral form, and some patients do move between forms or doses once they've reached a stable, long-term phase. Whether that's a fit for you is a conversation with your clinician, not a self-directed switch.

Managing a GLP-1 prescription long-term

Starting a GLP-1 medication is the beginning of a long-term relationship with your care team, not a short course with a fixed end date. The candidacy check, the visit schedule, the monitoring, and the eventual plateau are all part of the same plan — and each one is a reason to stay in touch with your clinician rather than a reason to second-guess the medication.

Sources

• U.S. Food and Drug Administration. "FDA Approves New Medication for Chronic Weight Management." FDA, https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management. Accessed September 29, 2026.
• U.S. Food and Drug Administration. "WEGOVY (semaglutide) Prescribing Information." FDA, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf. Accessed September 29, 2026.
• National Institute of Diabetes and Digestive and Kidney Diseases. "Prescription Medications to Treat Overweight & Obesity." NIDDK, https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity. Accessed October 5, 2026.
• Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., et al.; SURMOUNT-1 Investigators. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, vol. 387, no. 3, 2022, pp. 205–216, doi:10.1056/NEJMoa2206038. Accessed October 5, 2026.
• Jastreboff, A.M., le Roux, C.W., Stefanski, A., et al.; SURMOUNT-1 Investigators. "Tirzepatide for Obesity Treatment and Diabetes Prevention." New England Journal of Medicine, vol. 392, no. 10, 2025, pp. 958–971, doi:10.1056/NEJMoa2410819 (published online Nov. 13, 2024). Accessed October 5, 2026.